Prevalence of discordant immunological and virological responses in patients with AIDS under antiretro

Article Sidebar

PDF
Published: Mar 27, 2018
Keywords:
Antiretroviral therapy (ART) CD4 Viral load Discordantimmuno- virological response

Main Article Content

Pratoomrat Suklertlaew
Department of Medical Technology, Sawanpracharak Hospital,Sawanpracharak, Thailand 60000

Abstract

Background: The initiation of antiretroviral therapy (ART) generally leads to a rapid reduction in HIV-1 RNA plasma level and increase in peripheral CD4 cell counts. However, some patient experienced discordant response between undetectable HIV-1 RNA plasma level and the blunted CD4 cell count response. Some patients presented a different pattern of discordant response of sustained CD4 cell count response despite of persistent viremia.
Objective: To determine the prevalence of discordant immunological and virological responses in patients with AIDS receiving ART.
Setting: HIV clinic, department of medicine, Sawanpracharak hospital, Nakhonsawan province.
Study design: Retrospective description study.
Method: Data were obtained by reviewing of patient records registered at HIV clinic from January 1st 2015 to December 31st 2015. Immunological response defined as a CD4 cell count > 350 cells/µl and viral suppression was defined as viral load level<50 copies/ ml or undetectable after six months of ART commence­ment. Research data were presented into 3 groups of immuno-virologic responders including concordant responders, concordant non-responders and discordant responders. Descriptive statistic was presented with frequency and percentage.
Result: Total of 3,933 patients, there were 2,096 male patients. There was 73.7% of patient experienced favorable concordant response while 26.3% represented the discordant response. Among those of discordant response, 24% had virological response only and 2.3% had immunological response only. The percentage of discordant response in male group (32.1%) was higher than the female group (19.5%).
Conclusion: At Sawanpracharak hospital, the prevalence of discordant immunovirological responses in AIDS patients after six months of ART treatment was 26.3%. The discordant responses were higher in male than those of female patient.

Article Details

How to Cite
Suklertlaew, P. (2018). Prevalence of discordant immunological and virological responses in patients with AIDS under antiretro. MEDICAL JOURNAL OF SISAKET SURIN BURIRAM HOSPITALS, 32(2), 79–89. retrieved from https://he02.tci-thaijo.org/index.php/MJSSBH/article/view/116882
Issue
Vol. 32 No. 2 (2017): May - August 2017
Section
Original Articles

References

1. UNAIDS. Fact sheet-Latest statistics on the status of the AIDS epidermics. [online] 2016 [ 2017 May 20]. Available from :URL:https://www.unaids.org/ sites/default/files/media_asset/UN- AIDS_ FactSheet_en.pdf.

2. สำนักงานหลักประกันสุขภาพแห่งซาติ. สถานการณ์เอชไอวีและเอดส์ประเทศไทย พ.ศ. 2559. รายงานวันเอดส์โลก 2559:3.

3. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M. Life expectancy of individuals on combi­nation antiretroviral therapy in high- income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 48:293-9.

4. The Antiretroviral Therapy (ART) Cohort Collaboration. The Antiretro­viral Therapy (ART) Cohort Collabora­tion. Prognosis of HIV-1 infects patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185-97.

5. Kumar RS. Immunovirological discord­ance in HIV. Medicine update 2012;22:89-93.

6. ศักดิ์ชัย เดชตรัยรัตน์. Discordant respons­es in patients being treated in Chiang-mai. รายงานการประชุมวิชาการเอดส์และโฟไซโทรเมทรี ประจำปี พ.ศ.2551;14:11.

7. Nicastri E, Chiesi A, Angeletti c, Sarma-ti I, Palmisano L, Geraci A, et al. Clinical outcome after 4 year follow-up of HIV-sero positive subjects with incomplete virologic or immuno­logic response to HAART. J Med Virol 2005; 76:153-60.

8. Renaud M, Katlama C, Mallet A, Calvez V, Carcelan G, Tubiana R, et al. Deter­minants of paradoxical CD4 cell reconstitution after protease inhibi­tor-containing antiretroviral regimen. AIDS. 1999;13:669-76.

9. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein p, et al. Discord­ant immunologic and virologic responses to highly active antiretrovi­ral therapy are associated with increased mortality and poor adher­ence to therapy. J Acquir Immune Defic Syndr 2005;40:441-6.

10. Tan R, Westfall AO,Willig JH, Mugave-ro MJ, Saag MS, Kaslow RA, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretrovi­ral therapy. J Acquir Immune Defic Syndr.2008;47:553-8.

11. Piketty C, Castiel P, Belec L, Batisse D, Mohamed AS, Gilquin J, et al. Discrep­ant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-50.

12. Grabar S, Le Moing V, Goujard c, Leport c, Kazatchkine MD, Castagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiret­roviral therapy. Ann Intern Med. 2000;133:401-10.

13. Tuboi SH, Brinkhof MWG, Egger M, Stone RA, Braitstein p, Nash D, et al. Discordant responses to potent an­tiretroviral treatment in previously naive HIV-1 infected adults initiating treatment in resource-contrained countries. The antiretroviral therapy in low-income countries (ART-LINC) collaboration J Acquir Immune Defic Syndr. 2007;45:52-9.

14. Gutierrez F, Padilla S, Masia M, Iribarren JA, Moreno S, Viciana p, et al. Patients characteristics and clinical implica­tions of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 2008;6:100-7.

15. Florence E, Lundgren J, Dreezen c, Fisher M, Kirk o, Blaxhult A, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the Euro SIDA study. HIV Med. 2003;4:255-62.

16. Barreiro PM, Dona MC, Castilla J, Sori­ano V. Patterns of response(CD4 cell count and viral load) at 6 months in HIV infect patients on highly active antiretroviral therapy. AIDS. 1999;13:525-6.

17. Gilson R, Man S-L, Copas A, Rider A, Forsyth S, Hill T, et al. Discordant response on stating highly active antiretroviral therapy: suboptimal CD4 increase despite early viral suppres­sion in the UK Collaborative HIV Cohort (UK CHIC) study. HIV Med 2010;11:152-60.

18. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkines MD. Longterm clinical outcome of human immunodeficiency virus-infect­ed patients with discordant immuno­logic and viralogic response to a protease inhibitor containing regimen. J infects Dis. 2001;183:25.

19. Nicastri E, Angeletti C, Palmisano L, Sarmati, Chiesi A, Geraci A, et al. Gender differences in clinical progression of HIV-1 infected individ­uals during long term highly active antiretroviral therapy. AIDS. 2005;19:577-83.

20. Falster K, Petoumenos K, Chuah J, Mijch A, Mullhall B, Kelly M, et al. Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune defic Syndr.2009;50:307-13.

21. Kelley CF, Kitchen CMR, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long term antiretro­viral therapy .Clin Infect Dis. 2008;47:1093-101.

22. PCL Hospitality Co., Ltd. CD4 counts by Flow cytometry FC 500 Beckman Coulter Inc CA 92821 (Monograph on the Internet). USA; 2004 [Cited 2016 May 15]. Available form: https://www. rpciflow.org/pdfs/manuals/fc500/ FC500%20lnstruction%20Manual.pdf.

23. Abbott Laboratories Ltd. Abbott Real Time HIV-1. Abbott Molecular Inc. IL 60018 (Monograph on the Internet). USA; 2012 [Cited 2016 June 10], Avail­able form:https://www.molecular. abbott/sal/en-us/staticAssets/ realtime-hiv-l-package-insert.pdf.

24. Grabar S, Lousignian I, Sobel A, Le Bras P, Gasmault J, Enel P, et al. Immuno­logic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS: 2004;18:2029-2038.

25. Sachdeva N, Asthania V, Brewer Th, Garcia D, Asthana D, Impaired restora­tion of plasmacytoid dendritic cells in HIV-1 infected patients with poor CD4 T cell reconstitution is associated with decrease in capacity to produce IFN-alpha but not proinflammatory cytokines, J Immunol 2008:181:2887-97.

26. Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernaconi E, et al. CD4+ T cell count recovery in HIV type 1- infected patients is inde­pendent of class of antiretroviral therapy. Clin Infect Dis 2008;47:1093­101.

27. Levy Y, Lacabaratz C, Weiss L, Viard JD, Goujard C, Levievre JD, et al. Enhanced T cell recovery in HIV-1 infected adults through IL-7 treat­ment. J Clin Invest 2009;119:997­1007.

28. Douek DC, McFarland RD, Keiser PH, Gage EA, Messey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infec­tion. Nature 1998;396(6712): 690-695.